A groundbreaking study has shed light on the complex interactions between dystrophin, a protein critical to muscle stability, and its partner protein, dystrobrevin, offering new pathways for ...

Studies involving the selective restoration of membrane bound nNOS to dystrophin-deficient skeletal muscle will address some of these issues. In addition to shedding light on the function of the ...

A new study has shed light on the complex interactions between dystrophin, a protein critical to muscle stability, and its partner protein, dystrobrevin, offering new pathways for understanding and ...

Revidia Therapeutics Inc., a cardiac regenerative medicine company developing first-in-class small molecule drug therapies for heart injury, has announced that it has expanded its leadership team in ...

Newer therapies like PGN-EDO51 that target exon skipping are considered promising pathways to slow disease progression by restoring partial dystrophin function.

This is due to a fault in the gene producing dystrophin. Muscles to become weaker ... it affects the ability to breathe as well as the function of the heart, as the heart is a muscle too.

Capricor's biologics license application for deramiocel (CAP-1002) is draws largely on the Phase 2 HOPE-2 trial and its ...

Pfizer has reported that its Phase III CIFFREO clinical trial of investigational mini-dystrophin gene therapy ... no significant improvement in motor function was observed in the gene therapy ...